臨床婦人科産科69巻3号

2015年04月発行

今月の臨床 早産の予知・予防の新たな展開 早産の予防

4．早産予防とオメガ3（ω3）脂肪酸療法の展望

著者： 山下亜紀¹

所属機関： ¹東京大学医学部産婦人科

ページ範囲：P.320 - P.325

●自然早産の主要な原因の1つは，感染，炎症であり，その予防のためには抗菌薬治療だけでなく，すでに起こっている過剰な炎症を抑えることが重要である．

●オメガ3（ω3）脂肪酸は抗炎症作用をもっており，多く摂取することで早産の予防につながる可能性がある．

●近年，同定されたω3脂肪酸代謝物レゾルビンは，積極的な炎症収束作用をもち，将来の早産治療薬への応用が期待される．

参考文献

1） Christiaens I, et al : Inflammatory processes in preterm and term parturition. J Reprod Immunol 79 : 50─57, 2008

2） Gibbs RS : Chorioamnionitis and bacterial vaginosis. Am J Obstet Gynecol 169 : 460─462, 1993

3） Slattery MM, Morrison JJ : Preterm delivery. Lancet 360 : 1489─1497, 2002

4） Adams-Chapman I : Long-Term Impact of Infection on the Preterm Neonate. Semin. Perinatol 36 : 462─470, 2012

5） Chetty A, et al : The role of IL-6 and IL-11 in hyperoxic injury in developing lung. Pediatr Pulmonol 43 : 297─304, 2008

6） Mwaniki MK, et al : Long-term neurodevelopmental outcomes after intrauterine and neonatal insults : A systematic review. Lancet 379 : 445─452, 2012

7） Sorokin Y, et al : Maternal serum interleukin-6, c-reactive protein, and matrix metalloproteinase-9 concentrations as risk factors for preterm birth＜32 weeks and adverse neonatal outcomes. Am J Perinatol 27 : 631─639, 2010

8） Lee PR, et al : Therapeutic effect of cyclo-oxygenase inhibitors with different isoform selectivity in lipopolysaccharide-induced preterm birth in mice. Am J Obstet Gynecol 189 : 261─266, 2003

9） Sakai M, et al : Evaluation of the tocolytic effect of a selective cyclooxygenase-2 inhibitor in a mouse model of lipopolysaccharide-induced preterm delivery. Mol Hum Reprod 7 : 595─602, 2001

10） Yousif MH, Thulesius O : Tocolytic effect of the cyclooxygenase-2 inhibitor, meloxicam : studies on uterine contractions in the rat. J Pharm Pharmacol 50 : 681─685, 1998

11） Serhan CN, et al : Resolvins, docosatrienes, and neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered endogenous epimers : An overview of their protective roles in catabasis. Prostaglandins Other Lipid Mediat 73 : 155─172, 2004

12） Schwab JM, et al : Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 447 : 869─874, 2007

13） Tjonahen E, et al : Resolvin E2 : Identification and Anti-Inflammatory Actions : Pivotal Role of Human 5-Lipoxygenase in Resolvin E Series Biosynthesis. Chem Biol 13 : 1193─1202, 2006

14） Arita M, et al : Resolvin E1, an endogenous lipid mediator derived from omega-3 eicosapentaenoic acid, protects against 2,4,6-trinitrobenzene sulfonic acid-induced colitis. Proc Natl Acad Sci U S A 102 : 7671─7676, 2005

15） Arita M, et al : Stereochemical assignment, antiinflammatory properties, and receptor for the omega-3 lipid mediator resolvin E1. J Exp Med 201 : 713─722, 2005

16） Isobe Y, et al : Stereochemical assignment and anti-inflammatory properties of the omega-3 lipid mediator resolvin E3. J Biochem 153 : 355─360, 2013

17） Yokoyama M, et al : Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients（JELIS） : a randomised open-label, blinded endpoint analysis. Lancet 369 : 1090─1098, 2007

18） Olsen SF, et al : Randomised controlled trial of effect of fish-oil supplementation on pregnancy duration. Lancet 339 : 1003─1007, 1992

19） Horvath A, et al : Effect of supplementation of women in high-risk pregnancies with long-chain polyunsaturated fatty acids on pregnancy outcomes and growth measures at birth : a meta-analysis of randomized controlled trials. Br J Nutr 98 : 253─259, 2007

20） Kang JX, et al : Transgenic mice : fat-1 mice convert n-6 to n-3 fatty acids. Nature 427 : 504, 2004

21） Yamashita A, et al : Increased tissue levels of omega-3 polyunsaturated fatty acids prevents pathological preterm birth. Sci Rep 3 : 3113, 2013